News

Respiratory Drug Delivery (RDD) 2012

Poster: High-Sensitivity Analysis of Crystallinity in Respirable Powders Using Low Frequency Shift-Raman Spectroscopy

Poster: Product Performance, Stability and Dose Proportionality of Glycopyrrolate Metered-Dose Inhaler with Sub-Microgram Doses Using Cosuspension Technology

Poster: The Effect of Valve Storage Conditions on pMDI Water Content

American Association of Pharmaceutical Scientists (AAPS)
2011 Annual Meeting

Poster: In Vitro Structural Data: Thermodynamic and Structural Properties of Porous Particles (pdf, 1.7mb)

Poster: In Vitro Performance Data: Proprietary Formulation Approach Generates Uniform and Stable MDI Cosuspensions (pdf, 780k)

European Respiratory Society (ERS) 2011 Annual Meeting

Poster: Phase 2b Results: PT003 (GFF MDI) Demonstrates Superior Inspiratory Capacity Compared to Tiotropium (pdf, 600k)

Poster: Phase 2b Results: Glycopyrrolate MDI Demonstrates Comparable Efficacy and Safety to Tiotropium (pdf, 300k)

American Thoracic Society 2011 International Conference

Poster: Phase 2b Results: PT003 (GFF MDI) Provides Statistically Significant Improvement in Lung Function vs Tiotropium and Foradil (pdf, 2mb)

Respiratory Drug Delivery (RDD) Europe 2011

Poster: Performance Advantages of Pearl Cosuspension Formulation Technology (pdf, 500k)

Poster: Development of Inhaled Mono, Dual and Triple Combinations without Coformulation Effect (pdf, 3.1mb)

European Respiratory Society Annual Congress 2010

Poster: Phase 1/2a Results: Dose of Glycopyrrolate MDI Identified as Comparable to Approved Dose of Tiotropium (pdf, 1.5mb)

Poster: Phase 1/2a Results: Dose of Formoterol Fumarate MDI Identified as Comparable to Approved Dose of Foradil (pdf, 1.5mb)

American Thoracic Society 2010 International Conference

Poster: Phase 1 Study Results: PT003 (GFF MDI) Combination Bronchodilator Found to be Safe and Well Tolerated (pdf, 1.7mb)

Poster: Phase 1/2a Results: Glycopyrrolate MDI Demonstrates Comparable Efficacy and Safety to Tiotropium (pdf, 1.8mb)

Poster: Phase 1/2a Results: Formoterol Fumarate MDI Demonstrates Comparable Efficacy and Safety to Foradil (pdf, 1.8mb)

Poster: Stability Results: Glycopyrrolate MDI and Formoterol Fumarate MDI Shown to be Physically and Chemically Stable (pdf, 2.7mb)